Reaction

Apparent Death reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,605 reports · 58 co-occurring drugs

As of the last recalculation, Apparent Death appears in 3,605 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is CANAKINUMAB (PRR 189.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Canakinumab	324	189.9	195.7
Anakinra	322	123.0	125.4
Minocycline	68	34.3	34.5
Sulfasalazine	348	28.3	28.4
Leflunomide	347	21.1	21.1
Tocilizumab	354	19.8	19.8
Hydroxychloroquine Sulfate	281	19.2	19.3
Hydroxychloroquine	200	16.3	16.4
Abatacept	349	16.0	16.0
Infliximab	377	11.0	11.0
Rituximab	315	9.3	9.3
Rivastigmine	30	9.3	9.3
Valsartan And Hydrochlorothiazide	19	8.1	8.1
Doxyclycline Hyclate	21	7.2	7.2
Captopril	11	6.6	6.6
Ziprasidone Mesylate	16	6.5	6.5
Fluticasone Propionate And Salmeterol	41	5.7	5.7
Pregabalin	237	5.3	5.3
Methotrexate	355	5.3	5.3
Ziprasidone	16	5.3	5.3
Extended Phenytoin Sodium	15	5.2	5.2
Methotrexate Sodium	383	5.0	5.0
Thyroid, Porcine	9	4.9	4.9
Umeclidinium Bromide And Vilanterol Trifenatate	14	4.9	4.9
Theophylline Anhydrous	10	4.7	4.7
Tofacitinib	141	4.6	4.6
Theophylline	9	4.5	4.5
Adalimumab	483	4.4	4.4
Meperidine Hydrochloride	7	4.4	4.4
Etanercept	411	4.3	4.3
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	15	4.2	4.2
Naproxen Sodium, Pseudoephedrine Hydrochloride	15	4.2	4.2
Amlodipine Besylate And Valsartan	8	4.2	4.2
Deferasirox	19	4.2	4.2
Sacubitril And Valsartan	80	4.0	4.0
Salmeterol Xinafoate	6	4.0	4.0
Budesonide And Formoterol Fumarate Dihydrate	63	3.8	3.8
Oxycodone	118	3.7	3.7
Fluticasone Propionate And Salmeterol Xinafoate	37	3.6	3.6
Omalizumab	51	3.5	3.5
Nilotinib	16	3.1	3.1
Glatiramer Acetate	32	3.1	3.1
Insulin Glulisine	5	2.8	2.8
Testosterone Cypionate	4	2.6	2.6
Ticagrelor	14	2.5	2.5
Patiromer	6	2.5	2.5
Desvenlafaxine Succinate	11	2.4	2.4
Dofetilide	4	2.2	2.2
Buprenorphine Hydrochloride, Naloxone Hydrochloride	9	2.2	2.2
Golimumab	31	2.1	2.1
Lurasidone Hydrochloride	7	1.9	1.9
Varenicline Tartrate	26	1.9	1.9
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	10	1.9	1.9
Panitumumab	5	1.8	1.8
Ambrisentan	37	1.7	1.7
Pazopanib Hydrochloride	8	1.7	1.7
Enzalutamide	15	1.5	1.5
Orlistat	5	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.